檢索結果 - David Fabrizio

Refine Results
  1. 1
    Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies

    Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies 由 Ryan J. Hartmaier, Jehad Charo, David Fabrizio, Michael E. Goldberg, Lee A. Albacker, William Pao, Juliann Chmielecki

    出版 2017
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence

    Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence 由 Samuel J. Klempner, David Fabrizio, Shalmali Bane, Marcia Reinhart, Tim Peoples, Siraj M. Ali, Ethan S. Sokol, Garrett M. Frampton, Alexa B. Schrock, Rachel Anhorn, Prasanth Reddy

    出版 2019
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  3. 3
    DRAGON: A Member of the Repulsive Guidance Molecule-Related Family of Neuronal- and Muscle-Expressed Membrane Proteins Is Regulated by DRG11 and Has Neuronal Adhesive Properties

    DRAGON: A Member of the Repulsive Guidance Molecule-Related Family of Neuronal- and Muscle-Expressed Membrane Proteins Is Regulated by DRG11 and Has Neuronal Adhesive Properties 由 Tarek A. Samad, Ashok Srinivasan, Laurie A. Karchewski, Sung‐Jin Jeong, Jason Campagna, Ru‐Rong Ji, David Fabrizio, Ying Zhang, Herbert Y. Lin, Esther Bell, Clifford J. Woolf

    出版 2004
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma

    Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma 由 Celina Ang, Samuel J. Klempner, Siraj M. Ali, Russell W. Madison, Jeffrey S. Ross, Eric A. Severson, David Fabrizio, Aaron M. Goodman, Razelle Kurzrock, James Suh, Sherri Z. Millis

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Prevalence of<i>PDL1</i>Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors

    Prevalence of<i>PDL1</i>Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors 由 Aaron M. Goodman, David Piccioni, Shumei Kato, Amélie Boichard, Huan‐You Wang, Garrett M. Frampton, Scott M. Lippman, Caitlin Connelly, David Fabrizio, Vincent A. Miller, Jason K. Sicklick, Razelle Kurzrock

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors

    Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors 由 Changxia Shao, Gerald Li, Lingkang Huang, Scott K. Pruitt, Emily Castellanos, Garrett M. Frampton, Kenneth R. Carson, Tamara Snow, Gaurav Singal, David Fabrizio, Brian M. Alexander, Fan Jin, Wei Zhou

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population

    Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population 由 C. Benedikt Westphalen, Matthew Krebs, C. Le Tourneau, Ethan Sokol, Sophia L. Maund, Timothy R. Wilson, Dexter X. Jin, Justin Y. Newberg, David Fabrizio, L. Véronèse, M. Thomas, Filippo de Braud

    出版 2021
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers

    High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers 由 Paul Riviere, Aaron M. Goodman, Ryosuke Okamura, Donald A. Barkauskas, Theresa J. Whitchurch, Suzanna Lee, Noor Khalid, Rachel Collier, Manvita Mareboina, Garrett M. Frampton, David Fabrizio, Andrew B. Sharabi, Shumei Kato, Razelle Kurzrock

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    DRAGON, a Bone Morphogenetic Protein Co-receptor

    DRAGON, a Bone Morphogenetic Protein Co-receptor 由 Tarek A. Samad, Anuradha Rebbapragada, Esther Bell, Ying E. Zhang, Yisrael Sidis, Sung‐Jin Jeong, Jason Campagna, Stephen Perusini, David Fabrizio, Alan L. Schneyer, Herbert Y. Lin, Ali H. Brivanlou, Liliana Attisano, Clifford J. Woolf

    出版 2005
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK)

    Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK) 由 David R. Gandara, Marcin Kowanetz, Tony Mok, Achim Rittmeyer, Louis Fehrenbacher, David Fabrizio, Geoff Otto, Christine M. Malboeuf, Daniel S. Lieber, Sarah Paul, Lukas C. Amler, Todd Riehl, Erica Schleifman, Craig Cummings, P. Hegde, Wei Zou, Anna Sandler, M. Ballinger, David S. Shames

    出版 2017
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in <i>ERBB2</i> and <i>ERBB3</i>

    Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in <i>ERBB2</i> and <i>ERBB3</i> 由 Jeffrey S. Ross, Marwan Fakih, Siraj M. Ali, Julia A. Elvin, Alexa B. Schrock, James Suh, Jo‐Anne Vergilio, Shakti Ramkissoon, Eric A. Severson, Sugganth Daniel, David Fabrizio, Garrett M. Frampton, James Sun, Vincent A. Miller, Philip J. Stephens, Laurie M. Gay

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition

    Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition 由 David Fabrizio, Thomas J. George, Richard F. Dunne, Garrett M. Frampton, James Sun, Kyle Gowen, Mark Kennedy, Joel Greenbowe, Alexa B. Schrock, Aram F. Hezel, Jeffrey S. Ross, P. J. Stephens, Siraj M. Ali, Vincent A. Miller, Marwan Fakih, Samuel J. Klempner

    出版 2018
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability–High Cases in 67,000 Patient Samples

    A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability–High Cases in 67,000 Patient S... 由 Sally E. Trabucco, Kyle Gowen, Sophia L. Maund, Eric M. Sanford, David Fabrizio, Michael J. Hall, Evgeny Yakirevich, Jeffrey P. Gregg, Phil Stephens, Garrett M. Frampton, Priti S. Hegde, Vincent A. Miller, Jeffrey S. Ross, Ryan J. Hartmaier, Shih-Min A. Huang, James Sun

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

    Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial 由 Edward S. Kim, Vamsidhar Velcheti, Tarek Mekhail, Cindy Yun, Sarah M. Shagan, Sylvia Hu, Young Kwang Chae, Ticiana Leal, Jonathan E. Dowell, Michaela L. Tsai, Christopher Dakhil, Philip J. Stella, Yanling Jin, David S. Shames, Erica Schleifman, David Fabrizio, See Phan, Mark A. Socinski

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors

    Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors 由 Jessica Lee, Smruthy Sivakumar, Alexa B. Schrock, Russell W. Madison, David Fabrizio, Ole Gjoerup, Jeffrey S. Ross, Garrett M. Frampton, Pavel Napalkov, Meagan Montesion, Jennifer L. Schutzman, Xin Ye, Priti S. Hegde, Misako Nagasaka, Geoffrey R. Oxnard, Ethan Sokol, Sai‐Hong Ignatius Ou, Zhen Shi

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

    A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer 由 Zoe J. Assaf, Wei Zou, Alexander D. Fine, Mark A. Socinski, Amanda Young, Doron Lipson, Jonathan F. Freidin, Mark Kennedy, Eliana Polisecki, Makoto Nishio, David Fabrizio, Geoffrey R. Oxnard, Craig Cummings, Anja Rode, Martin Reck, Namrata S. Patil, Mark Lee, David S. Shames, Katja Schulze

    出版 2023
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer

    Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer 由 Christopher J. Sweeney, Russell Petry, Chang Xu, Merrida Childress, Jie He, David Fabrizio, Ole Gjoerup, Samantha Morley, Timothy Catlett, Zoe J. Assaf, Kobe Yuen, Matthew Wongchenko, Kalpit Shah, Pratyush Gupta, Priti Hegde, Lincoln W. Pasquina, Sanjeev Mariathasan, Ryon P. Graf, Thomas Powles

    出版 2024
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies

    Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies 由 Jeffrey S. Ross, Laurie M. Gay, K. Wang, Jo‐Anne Vergilio, James Suh, Shakti Ramkissoon, Hilary Somerset, Jennifer M. Johnson, Jeffery S. Russell, Siraj M. Ali, Alexa B. Schrock, David Fabrizio, Garrett M. Frampton, V.A. Miller, Philip J. Stephens, Julia A. Elvin, Daniel W. Bowles

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

    Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L no... 由 Mark A. Socinski, Vamsidhar Velcheti, Tarek Mekhail, Y.K. Chae, Ticiana Leal, J.E. Dowell, Ming-Hung Tsai, Christopher Dakhil, Philip J. Stella, Vincent K. Shen, Sylvia Hu, S.M. Paul, David S. Shames, Erica Schleifman, David Fabrizio, Michaeł Nowicki, C. Yun, S. Phan, E.S. Kim

    出版 2019
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer

    A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer 由 Kuei‐Ting Chen, Russell W. Madison, Jay A. Moore, Dexter X. Jin, Zoë Fleischmann, Justin Y. Newberg, Alexa B. Schrock, Neeru Bhardwaj, Katherine T Lofgren, Jie He, Garrett M. Frampton, Priti Hegde, David Fabrizio, Michael J. Pishvaian, Ericka M. Ebot, Aatur D. Singhi, Ethan Sokol

    出版 2023
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: